Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

NCT07393425 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HER2 + Breast Cancer

Interventions

DRUG: Trastuzumab Deruxtecan
DRUG: Pertuzumab
DRUG: Taxane Chemotherapy
DRUG: Trastuzumab (or biosimilar)
DRUG: Pyrotinib 320mg

Sponsor

Shanghai Jiao Tong University School of Medicine

Collaborators

[object Object]